News Releases 2015
First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
Faron Pharmaceuticals Ltd, the clinical stage biopharmaceutical company, is pleased to announce the enrolment of the first patient in the Phase III INTEREST clinical programme for Traumakine® for the treatment of acute respiratory distress syndrome (“ARDS”).
Faron Pharmaceuticals Ltd is pleased to announce that Tekes, the Finnish Funding Agency for Innovation (www.tekes.fi) has granted €1,535,100 in funding to progress the preclinical development of Clevegen, Faron´s novel cancer immunotherapy drug candidate. The funding awarded is a government loan , which covers 50 per cent of the budgeted cost of the preclinical development of Clevegen.
Key Publication on Novel Cancer Immunotherapy Mechanism Related to Clevegen in Journal of Immunology
The Journal of Immunology paper outlines the functional role of Clever-1 (also known as Stabilin-1) in immune responses. According to this Palani et al. study (2016), the study data defines Clever-1 as a new immunosuppressive molecule and suggests that Clever-1 may dampen pro-inflammatory reactions in vivo, especially when expressed on the surface of monocytes/macrophages.
Admission to AIM and first day of dealings, £10 million fundraise to progress Phase III clinical trial
Faron Pharmaceuticals Oy ("Faron”), the clinical stage biopharmaceutical company, is pleased to announce the commencement of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. today under the ticker FARN and the ISIN number FI4000153309. This follows a successful placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary share (the “Fundraising”).
Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
Under the agreement, Faron will have access to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody.
Faron Pharmaceuticals Oy announces 7 September 2015 its intention to raise new funds through a placing and offer for subscription and to apply for admission of its ordinary shares to trading on the AIM market of the London Stock Exchange.
One of the Faron Founders and sources of innovation, Academy Professor Sirpa Jalkanen, has been conferred the honorary title of Academician of Science by the President of the Republic of Finland.
Faron is now located in the Intelligate II building in Turku Science Park.
Faron announced today a collaboration with the Turku PET Center, one of the largest centers in Europe, on the development of its novel cancer immunotherapy Clevegen.
Faron Pharmaceuticals and China Medical System Holdings enter into strategic agreement for the development of Traumakine® in China, Hong Kong, Macao and Taiwan
€5 million equity investment made by A&B Ltd